Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1999-02-23
1999-12-28
Elliott, George C.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 245, 536 243, 536 231, 536 232, 435 911, 435 9131, 435325, 435 6, 514 44, C07H 2102, C07H 2104, C12Q 168, A61K 4800
Patent
active
060083441
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2 Group IV. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2 Group IV. Methods of using these compounds for modulation of Phospholipase A2 Group IV expression and for treatment of diseases associated with expression of Phospholipase A2 Group IV are provided.
REFERENCES:
Basavappa et al., Swelling-induced arachidonic acid release via the 85-kDa cPLA2 in human neuroblastoma cells, J. Neurophysiol., 1998, 79:1441-1449.
Burke et al., A beta-lactam inhibitor of cytosolic phospholipase A2 which acts in a competitive, reversible manner at the lipid/water interface, J. Enzyme Inhib., 1998, 13:195-206.
Gresham et al., Increased synthesis of high-molecular-weight cPLA2 mediates early UV- induced PGE2 in human skin, Am. J. Physiol., 1996, 270:C1037-1050.
Kramer et al., Structure, function and regulation of Ca2+-sensitive cytosolic phospholipase A2 (cPLA2), FEBS Lett., 1997, 410:49-53.
Kramer et al., Cytosolic phospholipase A2 (cPLA2) and lipid mediator release in the brain, J. Lipid Mediat. Cell Signal., 1996, 14:3-47.
Locati et al., Inhibition of monocyte chemotaxis to C-C chemokines by antisense oligonucleotide for cytosolic phospholipase A2 J. Biol. Chem., 1996, 271:6010-6016.
Murakami et al., Regulatory functions of phospholipase A2 Crit. Rev. Immunol., 1997, 17:225-283.
OBrien et al., Sustained phosphorylation of cytosolic phospholipase A2 accompanies cycloheximide- and adenovirus-induced susceptibility to TNF [In Process Citation], J. Immunol., 1998, 161:1525-1532.
Stephenson et al., Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain, Neurobiol. Dis., 1996, 3:51-63.
Wu et al., 1,25-Dihydroxyvitamin D3 protects human leukemic cells from tumor necrosis factor-induced apoptosis via inactivation of cytosolic phospholipase A2 Cancer Res., 1998, 58:633-640.
Bennett C. Frank
Cowsert Lex M.
Elliott George C.
Epps Janet
Isis Pharmaceuticals , Inc.
LandOfFree
Antisense modulation of phospholipase A2 group IV expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of phospholipase A2 group IV expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of phospholipase A2 group IV expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2383263